Evidence map›Paper›PMID 29293525›Full record

ArticlePloS one2018

Integrative network analysis highlights biological processes underlying GLP-1 stimulated insulin secretion: A DIRECT study.

Valborg Gudmundsdottir, Helle Krogh Pedersen, Karla Viviani Allebrandt, Caroline Brorsson, Nienke van Leeuwen, Karina Banasik, Anubha Mahajan, Christopher J Groves, Martijn van de Bunt, Adem Y Dawed and 18 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. GDI2 protein: research progress and its mechanisms in diseases.Frontiers in cell and developmental biology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Glucagon-like peptide 1 (GLP-1).Molecular metabolism · 2019 · on this map
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 13 institutions in 5 countries.

Valborg GudmundsdottirDepartment of Bio and Health Informatics, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0002-7459-1603
Helle Krogh PedersenDepartment of Bio and Health Informatics, Technical University of Denmark, Kongens Lyngby, Denmark.
Karla Viviani AllebrandtDepartment of Translational Bioinformatics, R&D Operations, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt, Germany.
Caroline BrorssonDepartment of Bio and Health Informatics, Technical University of Denmark, Kongens Lyngby, Denmark.
Nienke van LeeuwenDepartment of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands.
Karina BanasikNovo Nordisk Foundation Center for Protein Research, Disease Systems Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Anubha MahajanOxford NIHR Biomedical Research Center, Oxford, United Kingdom.
Christopher J GrovesOxford Center for Diabetes Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom.
Martijn van de BuntOxford NIHR Biomedical Research Center, Oxford, United Kingdom.
Adem Y DawedDivision of Molecular & Clinical Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom.
Andreas FritscheDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Eberhard Karls University Tübingen, Member of the German Centre for Diabetes Research (DZD), Tübingen, Germany.
Harald StaigerInstitute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls University, Tübingen, Germany.
Annemarie M C Simonis-BikDepartment of Internal Medicine, Diabetes Center and Endocrinology, VU University Medical Center, Amsterdam, The Netherlands.
Joris DeelenSection Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Mark H H KramerDepartment of Internal Medicine, Diabetes Center and Endocrinology, VU University Medical Center, Amsterdam, The Netherlands.
Axel DietrichDepartment of Translational Bioinformatics, R&D Operations, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt, Germany.
Thomas HübschleDepartment GI Endocrinology, R&D Diabetes Division, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Frankfurt, Germany.
Gonneke WillemsenDepartment of Biological Psychology, Vrije Universiteit and the EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands.
Hans-Ulrich HäringDepartment of Internal Medicine, Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, Eberhard Karls University Tübingen, Member of the German Centre for Diabetes Research (DZD), Tübingen, Germany.
Eco J C de GeusDepartment of Biological Psychology, Vrije Universiteit and the EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands.
Dorret I BoomsmaDepartment of Biological Psychology, Vrije Universiteit and the EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands.
Elisabeth M W EekhoffDepartment of Internal Medicine, Diabetes Center and Endocrinology, VU University Medical Center, Amsterdam, The Netherlands.
Jorge FerrerSection of Epigenomics and Disease, Department of Medicine, Imperial College London, London, United Kingdom.
Mark I McCarthyWellcome Trust Center for Human Genetics, University of Oxford, Oxford, United Kingdom.
Ewan R PearsonDivision of Molecular & Clinical Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom.
Ramneek GuptaDepartment of Bio and Health Informatics, Technical University of Denmark, Kongens Lyngby, Denmark.
Søren BrunakDepartment of Bio and Health Informatics, Technical University of Denmark, Kongens Lyngby, Denmark.
Leen M 't HartDepartment of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands.
Technical University of Denmark · DKAmsterdam Public Health · NLAmsterdam UMC Location Vrije Universiteit Amsterdam · NLLeiden University Medical Center · NLSanofi (Germany) · DEDeutsches Diabetes-Zentrum e.V. · DEUniversity of Copenhagen · DKUniversity of Dundee · GBUniversity of Oxford · GBCentre for Human Genetics · GBCentro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ESOxford BioMedica (United Kingdom) · GBUniversity of Tübingen · DE

Funding

Medical Research Council MR/L02036X/1
6 · The paper itself

Abstract

Glucagon-like peptide 1 (GLP-1) stimulated insulin secretion has a considerable heritable component as estimated from twin studies, yet few genetic variants influencing this phenotype have been identified. We performed the first genome-wide association study (GWAS) of GLP-1 stimulated insulin secretion in non-diabetic individuals from the Netherlands Twin register (n = 126). This GWAS was enhanced using a tissue-specific protein-protein interaction network approach. We identified a beta-cell protein-protein interaction module that was significantly enriched for low gene scores based on the GWAS P-values and found support at the network level in an independent cohort from Tübingen, Germany (n = 100). Additionally, a polygenic risk score based on SNPs prioritized from the network was associated (P < 0.05) with glucose-stimulated insulin secretion phenotypes in up to 5,318 individuals in MAGIC cohorts. The network contains both known and novel genes in the context of insulin secretion and is enriched for members of the focal adhesion, extracellular-matrix receptor interaction, actin cytoskeleton regulation, Rap1 and PI3K-Akt signaling pathways. Adipose tissue is, like the beta-cell, one of the target tissues of GLP-1 and we thus hypothesized that similar networks might be functional in both tissues. In order to verify peripheral effects of GLP-1 stimulation, we compared the transcriptome profiling of ob/ob mice treated with liraglutide, a clinically used GLP-1 receptor agonist, versus baseline controls. Some of the upstream regulators of differentially expressed genes in the white adipose tissue of ob/ob mice were also detected in the human beta-cell network of genes associated with GLP-1 stimulated insulin secretion. The findings provide biological insight into the mechanisms through which the effects of GLP-1 may be modulated and highlight a potential role of the beta-cell expressed genes RYR2, GDI2, KIAA0232, COL4A1 and COL4A2 in GLP-1 stimulated insulin secretion.

Indexed as

AnimalsGlucagon-Like Peptide 1HumansInsulinInsulin SecretionMiceGlucagon-Like Peptide 1Insulin

Identifiers

PMID29293525
PMCPMC5749727
OpenAlexW2781921611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.